MedTrace Logo

PROLIFICA - West African Treatment Cohort for Hepatitis B

NCT02129829 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1079

Last updated 2020-09-28

No results posted yet for this study

Summary

The West African Treatment Cohort for Hepatitis B (WATCH) study is a component of the European Commission Funded FP7 project PROLIFICA. It aims to evaluate a number of steps required to successfully treat patients with chronic hepatitis B virus infection to prevent cirrhosis and liver cancer. The first step is to determine whether screening for hepatitis B using a point of care test is feasible and effective. The second is to monitor linkage from screening into care. The third is to evaluate cheap non-invasive assessments to determine the need for treatment. The fourth is to determine what proportion of patients meet treatment eligibility criteria. The fifth step is to establish a treatment cohort which can be used to measure adherence to therapy and avoidance of HBV related complications. A parallel untreated cohort will be established to determine whether treatment criteria are relevant in this West African setting by monitoring for complications of HBV infection.

Conditions

Interventions

DRUG

Tenofovir disoproxil

Tenofovir disoproxil 245 mg once daily

Sponsors & Collaborators

  • Medical Research Council Unit, The Gambia

    collaborator OTHER

  • Department of State for Health and Social Welfare, The Gambia

    collaborator OTHER_GOV

  • UFR Sante de Thies, Senegal

    collaborator UNKNOWN

  • Cheikh Anta Diop University, Senegal

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • International Agency for Research on Cancer

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Mark Thursz, MD FRCP · Imperial College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • Senegal
  • The Gambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129829 on ClinicalTrials.gov